News
KPTI
1.060
-2.75%
-0.030
KARYOPHARM ANNOUNCES PRESENTATIONS IN ENDOMETRIAL CANCER AND MYELOFIBROSIS AT THE 2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING
Reuters · 1d ago
Karyopharm Therapeutics (KPTI) Gets a Buy from Piper Sandler
TipRanks · 3d ago
Weekly Report: what happened at KPTI last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at KPTI last week (0408-0412)?
Weekly Report · 04/15 09:06
Analysts Are Bullish on Top Healthcare Stocks: Ionis Pharmaceuticals (IONS), Intuitive Surgical (ISRG)
TipRanks · 04/09 11:00
Weekly Report: what happened at KPTI last week (0401-0405)?
Weekly Report · 04/08 09:06
Karyopharm Therapeutics (NASDAQ:KPTI) shareholders are up 14% this past week, but still in the red over the last three years
The Karyopharm Therapeutics Inc. Share price is up 75% in the last quarter. The company's share price has fallen 86% over the last three years. The share price of the company is down 23% over three years, and shareholders are down 60% for the year. The firm grew revenue at 7.6% per year, but the company doesn't make profits. Share price weakness can be a good sign for a company, but Karypharm Therapedutics may not be the best stock to buy.
Simply Wall St · 04/02 10:34
Weekly Report: what happened at KPTI last week (0325-0329)?
Weekly Report · 04/01 09:06
Weekly Report: what happened at KPTI last week (0318-0322)?
Weekly Report · 03/25 09:06
Weekly Report: what happened at KPTI last week (0311-0315)?
Weekly Report · 03/18 09:06
Onco360 Selected As The Preferred National Specialty Pharmacy Partner For Karyopharm's Product XPOVIO, A First-In-Class, XPO-1 Inhibitor
Onco360 is now the national specialty pharmacy network partner for Karyopharm's product XPOVIO (selinexor), a first-in-class, XPO-1 inhibitor. The drug is approved in multiple oncology indications for multiple myeloma. Only 50 percent of patients diagnosed with the incurable disease survive past five years.
Benzinga · 03/13 20:38
Weekly Report: what happened at KPTI last week (0304-0308)?
Weekly Report · 03/11 09:06
Big Pharma patent cliffs seen fueling oncology M&A this year
Big Pharma patent cliffs seen fueling oncology M&A this year. Around $182B in revenue is at risk over the next four years due to patent expirations. Cantor Fitzgerald sees between five and 17 acquisition deals for oncologists in 2014. The global market for cancer drugs is expected to grow from $180B in 2022 to $323B in 2028.
Seeking Alpha · 03/10 17:08
Karyopharm Therapeutics Inc: Statement of changes in beneficial ownership of securities
Press release · 03/05 14:06
Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI) and Siemens Healthineers AG (OtherSEMHF)
2 analysts have maintained Buy ratings on Karyopharm Therapeutics and Siemens Healthineers AG. The analyst consensus on the stock is a Strong Buy with an average price target of $5.80. The company’s shares are currently trading at $1.31.
TipRanks · 03/05 08:20
Weekly Report: what happened at KPTI last week (0226-0301)?
Weekly Report · 03/04 09:06
Barclays Gives a Buy Rating to Karyopharm Therapeutics (KPTI)
Karyopharm Therapeutics has an analyst consensus of Strong Buy, with a price target of $5.25. The company is developing drugs for the treatment of cancer and other major diseases. Peter Lawson has an average return of 12.3% and a 49.59% success rate on recommended stocks.
TipRanks · 03/04 07:55
RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)
RBC Capital analyst Brian Abrahams maintains a Buy rating on Karyopharm Therapeutics. The analyst consensus on the stock is a Strong Buy with an average price target of $5.33. The company is developing drugs for the treatment of cancer and other major diseases.
TipRanks · 03/01 12:28
Karyopharm Therapeutics Price Target Cut to $8.00/Share From $10.00 by HC Wainwright & Co.
Dow Jones · 03/01 12:20
Karyopharm Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/01 12:20
More
Webull provides a variety of real-time KPTI stock news. You can receive the latest news about Karyopharm Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.